| Catalog#: |
MK0452C |
| Product Name: |
Recombinant Cynomolgus IGFBP3, His tagged |
| Product Overview: |
Recombinant Cynomolgus IGFBP3 (Gly28-Lys291), fused with a polyhistide tag at the N-terminus, was produced in Human Cell. |
| Description: |
Insulin-like growth factor-binding proteins (IGFBPs) prolong the half-life of the IGFs, control bioavailability, activity, and distribution of insulin-like growth factor (IGF) through high-affinity IGFBP/IGF complexes. Six high-affinity IGF-binding proteins (IGFBP-1 to -6) have been identified. Human IGFBP3 is a widely expressed protein containing an IGFBP domain at the N-terminus and a thyroglobulin type-I domain. IGFBP3 forms a ternary complex of about 140 ~150 kDa with IGF1 or IGF2 and a glycoprotein ins |
| Source: |
HEK293 cells |
| Species: |
Cynomolgus |
| Tag: |
His |
| Formulation: |
Lyophilized from a 0.2μm filtered solution of PBS, pH 7.4. |
| Storage: |
Store under sterile conditions at -20°C to -80°C. Avoid repeated freeze-thaw cycles. |
| Reconstitution: |
It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4°C before opening to recover the entire contents. |
| Molecular Mass: |
The recombinant heterodimer of cynomolgus IGFBP3 comprises 284 amino acids and has a calculated molecular mass of 31.1 KDa. The apparent molecular mass of the protein is approximately 41-44 KDa respectively in SDS-PAGE. |
| Stability: |
Samples are stable for up to twelve months from date of receipt at -70℃. |
| Endotoxin: |
Less than 1.0 EU per μg as determined by the LAL method. |
| Notes: |
Research Use Only. Not for use in clinical procedures.Aoid repeated freeze-thaw cycles. |
